

## Waning of mRNA-1273 vaccine effectiveness against SARS-CoV-2 infection in Qatar

Laith J. Abu-Raddad, PhD<sup>1,2,3,4\*</sup>, Hiam Chemaitelly, PhD<sup>1,2</sup>, Houssein H. Ayoub, PhD<sup>5</sup>, Hadi M. Yassine, PhD<sup>6,7</sup>, Fatiha M. Benslimane, PhD<sup>6,7</sup>, Hebah A. Al Khatib, PhD<sup>6,7</sup>, Patrick Tang, MD PhD<sup>8</sup>, Mohammad R. Hasan<sup>8</sup>, Peter Coyle, MD<sup>6,9,10</sup>, Zaina Al Kanaani, PhD<sup>9</sup>, Einas Al Kuwari, MD<sup>9</sup>, Andrew Jeremijenko, MD<sup>9</sup>, Anvar Hassan Kaleeckal, MSc<sup>9</sup>, Ali Nizar Latif, MD<sup>9</sup>, Riyazuddin Mohammad Shaik, MSc<sup>9</sup>, Hanan F. Abdul Rahim, PhD<sup>11</sup>, Gheyath K. Nasrallah, PhD<sup>6,7</sup>, Mohamed Ghaith Al Kuwari, MD<sup>12</sup>, Adeel A. Butt, MBBS MS<sup>3,9</sup>, Hamad Eid Al Romaihi, MD<sup>13</sup>, Mohamed H. Al-Thani, MD<sup>13</sup>, Abdullatif Al Khal, MD<sup>9</sup>, and Roberto Bertollini, MD MPH<sup>13</sup>

<sup>1</sup>*Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar*

<sup>2</sup>*World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation – Education City, Doha, Qatar*

<sup>3</sup>*Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA*

<sup>4</sup>*Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar*

<sup>5</sup>*Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar*

<sup>6</sup>*Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar*

<sup>7</sup>*Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar*

<sup>8</sup>*Department of Pathology, Sidra Medicine, Doha, Qatar*

<sup>9</sup>*Hamad Medical Corporation, Doha, Qatar*

<sup>10</sup>*Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom*

<sup>11</sup>*College of Health Sciences, QU Health, Qatar University, Doha, Qatar*

<sup>12</sup>*Primary Health Care Corporation, Doha, Qatar*

<sup>13</sup>*Ministry of Public Health, Doha, Qatar*

**Word count:** Abstract: 266 words, Main Text: 2,216 words.

**Number of tables:** 7

**Number of figures:** 2

\*Correspondence to Professor Laith J. Abu-Raddad, E-mail: [lja2002@qatar-med.cornell.edu](mailto:lja2002@qatar-med.cornell.edu).

## Abstract

**BACKGROUND:** In early 2021, Qatar launched a mass immunization campaign with Moderna's mRNA-1273 COVID-19 vaccine. We assessed persistence of real-world mRNA-1273 effectiveness against SARS-CoV-2 infection and against COVID-19 hospitalization and death.

**METHODS:** Effectiveness was estimated using test-negative, case-control study design, between January 1 and December 5, 2021. Effectiveness was estimated against documented infection (a PCR-positive swab, regardless symptoms), and against any severe (acute-care hospitalization), critical (ICU hospitalization), or fatal COVID-19.

**RESULTS:** By December 5, 2021, 2,962 breakthrough infections had been recorded among those who received two mRNA-1273 doses. Of these infections, 19 progressed to severe COVID-19 and 4 to critical, but none to fatal disease. mRNA-1273 effectiveness against infection was negligible for the first two weeks after the first dose, increased to 65.5% (95% CI: 62.7-68.0%) 14 or more days after the first dose, and reached its peak at about 90% in the first three months after the second dose. Effectiveness declined gradually starting from the fourth month after the second dose and was below 50% by the 7<sup>th</sup> month after the second dose. Effectiveness against severe, critical, or fatal COVID-19 reached its peak at essentially 100% right after the second dose, and there was no evidence for declining effectiveness over time. Effectiveness against symptomatic versus asymptomatic infection demonstrated the same pattern of waning, but effectiveness against symptomatic infection was consistently higher than that against asymptomatic infection and waned more slowly.

**CONCLUSIONS:** mRNA-1273-induced protection against infection appears to wane month by month after the second dose. Meanwhile, protection against hospitalization and death appears robust with no evidence for waning for several months after the second dose.

## **Introduction**

In early 2021, Qatar launched a mass immunization campaign with Moderna's mRNA-1273<sup>1</sup> Coronavirus Disease 2019 (COVID-19) vaccine.<sup>2</sup> We assessed persistence of real-world mRNA-1273 effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and against COVID-19 hospitalization and death.

## **Methods**

### **Study population, data sources, and study design**

This study was conducted in the resident population of Qatar, applying the same methodology that was used recently to assess waning of BNT162b2<sup>6</sup> vaccine effectiveness in the same population.<sup>3</sup> A detailed description of this methodology can be found in Chemaitelly *et al.*<sup>3</sup> COVID-19 laboratory testing, vaccination, clinical infection data, and related demographic details were extracted from the national, federated SARS-CoV-2 databases that include all polymerase chain reaction (PCR) testing, COVID-19 vaccinations, and COVID-19 hospitalizations and deaths in Qatar since the start of the pandemic.

Every PCR test conducted in Qatar is classified on the basis of symptoms and the reason for testing (clinical symptoms, contact tracing, surveys or random testing campaigns, individual requests, routine healthcare testing, pre-travel, at port of entry, or other). Qatar has unusually young, diverse demographics, in that only 9% of its residents are  $\geq 50$  years of age, and 89% are expatriates from over 150 countries.<sup>7,8</sup> Nearly all individuals were vaccinated in Qatar, but if vaccinated elsewhere, those vaccinations were still recorded in the health system at the port of entry upon return to Qatar.

Vaccine effectiveness was estimated using the test-negative, case-control study design, a standard design for assessing vaccine effectiveness.<sup>2,9-16</sup> Cases (PCR-positive persons) and controls (PCR-negative persons) were matched one-to-two by sex, 10-year age group, nationality, reason for SARS-CoV-2 PCR testing, and calendar week of PCR testing to estimate vaccine effectiveness against SARS-CoV-2 infection; and one-to-five to estimate vaccine effectiveness against any severe, critical, or fatal COVID-19 (to improve statistical precision given the relatively small number of severe forms of COVID-19). Matching was performed to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar.<sup>8,17-20</sup>

Only the first PCR-positive test during the study was included for each case, and only the first PCR-negative test during the study was included for each control. PCR tests done for pre-travel or at the port of entry were excluded from analysis. All PCR-negative tests for persons included as cases were excluded from analysis. These inclusion and exclusion criteria were implemented to minimize different types of potential bias, as informed by prior analyses.<sup>3</sup>

All persons who received mixed vaccines, or who received a vaccine other than mRNA-1273, or who were tested by PCR after receiving a booster dose were excluded. Every case that met the inclusion criteria and that could be matched to a control was included in the analysis. Both PCR-test outcomes and vaccination status were ascertained at the time of the PCR test.

Effectiveness was estimated against documented infection (defined as a PCR-positive swab, regardless of the reason for PCR testing or the presence of symptoms), as well as against any severe,<sup>21</sup> critical,<sup>21</sup> or fatal<sup>22</sup> COVID-19. Classification of COVID-19 case severity (acute-care hospitalizations),<sup>21</sup> criticality (ICU hospitalizations),<sup>21</sup> and fatality<sup>22</sup> followed World Health Organization (WHO) guidelines, and assessments were made by trained medical personnel using individual chart reviews (Section S1).

Each person who had a positive PCR test result and hospital admission was subject to an infection severity assessment every three days until discharge or death, regardless of the length of the hospital stay or the time between the PCR-positive test and the final disease outcome. Individuals who progressed to severe,<sup>21</sup> critical,<sup>21</sup> or fatal<sup>22</sup> COVID-19 between the PCR-positive test result and the end of the study were classified based on their worst outcome, starting with death, followed by critical disease, and then severe disease.

Details of laboratory methods for real-time reverse-transcription PCR (RT-qPCR) testing are found in Section S2. All PCR testing was conducted at the Hamad Medical Corporation Central Laboratory or at Sidra Medicine Laboratory, following standardized protocols.

The study was approved by the Hamad Medical Corporation and Weill Cornell Medicine-Qatar Institutional Review Boards with a waiver of informed consent. Reporting of the study followed STROBE guidelines (Table S1).

### **Statistical analysis**

All records of PCR testing in Qatar during the study were included, but only samples of matched cases and controls were included in the analysis. Demographic characteristics of study samples were described using frequency distributions and measures of central tendency.

The odds ratio, comparing odds of vaccination among cases versus controls, and its associated 95% confidence interval (CI) were derived using conditional logistic regression, that is factoring the matching in the study design. This matching and analysis approach aims to minimize potential bias due to variation in epidemic phase,<sup>9,23</sup> gradual roll-out of vaccination during the study,<sup>9,23</sup> or other confounders.<sup>24,25</sup> CIs were not adjusted for multiplicity. Interactions were not investigated. Vaccine effectiveness at different time points and its associated 95% CI were then calculated by applying the following equation.<sup>9,10</sup>

Vaccine effectiveness =  $1 - \text{odds ratio of vaccination among cases versus controls}$ .

In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in that specific time-since-vaccination stratum and those unvaccinated (our reference group).

Only matched pairs of PCR-positive and PCR-negative persons, in which members of the pair were either unvaccinated or fell within each time-since-vaccination stratum were included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses. Effectiveness after the second dose was estimated month by month, where one month was defined as 30 days.

A sensitivity analysis was conducted by adjusting in the conditional logistic regression for prior infection and healthcare worker status, as healthcare workers were prioritized for vaccination and may have had a different risk of exposure to the infection. The analysis specifically adjusted for being a healthcare worker at Hamad Medical Corporation, the main public healthcare provider in Qatar and the nationally designated provider for all COVID-19 healthcare needs.

Vaccine effectiveness was also estimated against symptomatic infection, defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection, and against asymptomatic infection, defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection. In the latter case, PCR testing was done strictly as part of a survey or a random testing campaign. Vaccine effectiveness was further estimated by age group and for severe forms of COVID-19.

## **Results**

Between January 1 and December 5, 2021, 893,779 individuals received at least one mRNA-1273 dose and 887,726 completed the two-dose regimen. The median date for the first dose was May 27, 2021, and that for the second dose was June 27, 2021. The median time elapsed between the two doses was 28 days (interquartile range, 28-30 days). By December 5, 2021, 2,962 breakthrough infections had been recorded among those who received two doses. Of these infections, 19 progressed to severe COVID-19 and 4 to critical, but none to fatal disease.

Figure 1 depicts the process used to select the study population. Tables 1-3 show the characteristics of samples used in the analysis. Only ~35% of cases were diagnosed because of symptoms. The remaining cases were diagnosed because of PCR testing for contact tracing, surveys or random testing campaigns, individual requests, and routine healthcare testing.

mRNA-1273 effectiveness against infection was negligible for the first two weeks after the first dose, increased to 65.5% (95% CI: 62.7-68.0%) 14 or more days after the first dose, and reached its peak at about 90% in the first three months after the second dose (Figure 2 and Table 4).

Effectiveness declined gradually starting from the fourth month after the second dose and was below 50% by the 7<sup>th</sup> month after the second dose. Effectiveness against severe, critical, or fatal COVID-19 reached its peak at essentially 100% right after the second dose, and there was no evidence for declining effectiveness over time. Sensitivity analysis that adjusted for prior infection and healthcare worker status showed same pattern of waning (Table 5).

Effectiveness for those <50 years of age and those  $\geq 50$  were similar in absolute value and showed the same pattern of waning (Table 6). Effectiveness against symptomatic versus asymptomatic infection demonstrated the same pattern of waning, but effectiveness against symptomatic infection was consistently higher than that against asymptomatic infection and

waned more slowly (Figure 2 and Table 7). The above measures largely reflected effectiveness against the Beta and Delta variants that dominated incidence during the study.<sup>3-5</sup>

## **Discussion**

mRNA-1273-induced protection against infection appears to wane month by month after the second dose. Meanwhile, protection against hospitalization and death appears robust with no evidence for waning for several months after the second dose.

Since the immunization campaign prioritized vaccination of persons with severe or multiple chronic conditions and by age group, the observed pattern of waning of protection could theoretically be confounded by effects of age and comorbidities. Individual-level data on comorbid conditions were not available; therefore, they could not be explicitly factored into our analysis. However, only a small proportion of the study population may have had serious comorbid conditions. Only 9% of the population of Qatar are  $\geq 50$  years of age,<sup>7,8</sup> and 60% are young, expatriate craft and manual workers working in mega-development projects.<sup>19,20,26</sup> The national list of persons prioritized to receive the vaccine during the first phase of vaccine roll-out included only 19,800 individuals of all age groups with serious co-morbid conditions. Old age may serve as a partial proxy for co-morbid conditions. A similar pattern of waning of protection was observed for younger and older persons (Table 6). Notably, with the small proportion of Qatar's population being  $\geq 60$  years of age,<sup>7,8</sup> our findings may not be generalizable to other countries in which elderly citizens constitute a larger proportion of the total population.

Infection incidence was dominated sequentially by different variants,<sup>2-5,14,27,28</sup> thus, it is possible that waning of protection could be confounded by exposure to different variants at different times. However, this seems unlikely, as a similar pattern of waning was observed in our recent

study of the BNT162b2 vaccine for the Alpha,<sup>29</sup> Beta,<sup>29</sup> and Delta<sup>29</sup> variants in the same population.<sup>3</sup>

Vaccinated persons presumably have a higher social contact rate than unvaccinated persons, and they may also adhere less strictly to safety measures.<sup>30-32</sup> This behavior could reduce real-world effectiveness of the vaccine compared to its biological effectiveness, possibly explaining the waning of protection. Public health restrictions have been easing gradually in Qatar, but differently for vaccinated and unvaccinated persons. Many social, work, and travel activities presently require evidence of vaccination (a “health pass”) that is administered through a mandatory mobile app (the Ehteraz app). However, risk compensation is perhaps more likely to affect the overall estimate of effectiveness, rather than the observed waning of protection over time, unless such risk compensation increases with time after the second dose.

PCR testing in Qatar is done on a mass scale, such that about 5% of the population are tested every week.<sup>3</sup> About 75% of those diagnosed at present are diagnosed not because of symptoms, but because of routine testing.<sup>3</sup> It is possible that many asymptomatic infections were diagnosed among vaccinated persons that otherwise would have been missed. The higher ascertainment of infection may have reduced the effectiveness estimates. This is supported by the observed lower effectiveness against asymptomatic infection (Table 7).

Effectiveness was assessed using an observational, test-negative, case-control study design,<sup>9,10</sup> rather than a randomized, clinical trial design, in which cohorts of vaccinated and unvaccinated individuals were followed up. We were unable to use a cohort study design due to depletion of unvaccinated cohorts by the high vaccine coverage. However, the cohort study design applied earlier to the same population of Qatar yielded findings similar to those of the test-negative case-control design,<sup>2,14-16</sup> supporting the validity of this standard approach in assessing vaccine

effectiveness for respiratory tract infections.<sup>2,9-16</sup> The results of this study are also consistent with our earlier effectiveness estimates immediately after the first and second doses,<sup>2,16</sup> noting that estimated measures largely reflected effectiveness against the Beta and Delta variants that dominated incidence during that study.<sup>2-5,14,27,28</sup>

To rapidly scale up vaccination, some vaccination campaigns are conducted outside healthcare facilities; thus, records of vaccination are not immediately uploaded into the CERNER system, which tracks all vaccination records at the national level. This administrative time delay can introduce a misclassification bias of those vaccinated versus those unvaccinated. A sensitivity analysis investigating the impact of such potential bias, by assuming a 10% misclassification bias of those vaccinated and unvaccinated in Table 4, found very limited difference in estimated effectiveness. A key strength of the test-negative, case-control study design is that it is less susceptible to this form of bias.<sup>9,10</sup>

Nonetheless, one cannot exclude the possibility that in real-world data, bias could arise in unexpected ways, or from unknown sources, such as subtle differences in test-seeking behavior or changes in the pattern of testing with introduction of other testing modalities, such as rapid antigen testing.

Notwithstanding these limitations, consistent findings were reached, indicating a large effect size for the waning of vaccine protection over time, regardless of the reason for PCR testing, and regardless of the presence or absence of symptoms. Moreover, with the mass scale of PCR testing in Qatar,<sup>3</sup> the likelihood of bias is perhaps minimized. Extensive sensitivity and additional analyses were conducted to investigate effects of potential bias in our recent study for the BNT162b2 vaccine,<sup>3</sup> which used the same methodology as the present study. All analyses presented consistent findings of waning vaccine protection.

## **Acknowledgements**

We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, the Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine – Qatar for their diligent efforts and contributions to make this study possible.

The authors are grateful for support from the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core, both at Weill Cornell Medicine-Qatar, as well as for support provided by the Ministry of Public Health, Hamad Medical Corporation, and Sidra Medicine. The authors are also grateful for the Qatar Genome Programme and Qatar University Biomedical Research Center for institutional support for the reagents needed for the viral genome sequencing. Statements made herein are solely the responsibility of the authors.

The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article.

## **Author contributions**

LJA conceived and co-designed the study, led the statistical analyses, and co-wrote the first draft of the article. HC co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. PT and MRH conducted the multiplex, RT-qPCR variant screening and viral genome sequencing. HY, FMB, and HAK conducted viral genome sequencing. All authors contributed to data collection and acquisition, database development, discussion and interpretation of the results, and to the writing of the manuscript. All authors have read and approved the final manuscript.

## **Competing interests**


Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise we declare no competing interests.

## References

1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021;384:403-16.
2. Chemaitelly H, Yassine HM, Benslimane FM, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* 2021;27:1614-21.
3. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med* 2021.
4. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. *JAMA* 2021;326:1930-9.
5. Hasan MR, Kalikiri MKR, Mirza F, et al. Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar. *Int J Infect Dis* 2021;112:52-4.
6. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020;383:2603-15.
7. Planning and Statistics Authority-State of Qatar. Qatar Monthly Statistics. Available from: <https://www.psa.gov.qa/en/pages/default.aspx>. Accessed on: May 26, 2020. 2020.
8. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. *Sci Rep* 2021;11:6233.
9. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. *Vaccine* 2013;31:2165-8.
10. Verani JR, Baqui AH, Broome CV, et al. Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls. *Vaccine* 2017;35:3295-302.
11. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The Lancet* 2021;397:2461-2.
12. Nasreen S, He S, Chung H, et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. *medRxiv* 2021:2021.06.28.21259420.
13. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* 2021;385:585-94.
14. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for Covid Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* 2021;385:187-9.
15. Butt AA, Chemaitelly H, Al Khal A, et al. SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. *J Clin Invest* 2021;131.
16. Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med* 2021.
17. Ayoub HH, Chemaitelly H, Seedat S, et al. Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19. *J Glob Health* 2021;11:05005.
18. Coyle PV, Chemaitelly H, Ben Hadj Kacem MA, et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals. *iScience* 2021;24:102646.

19. Al-Thani MH, Farag E, Bertollini R, et al. SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. *Open Forum Infect Dis* 2021;8:ofab221.
20. Jeremijenko A, Chemaitelly H, Ayoub HH, et al. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. *Emerg Infect Dis* 2021;27:1343-52.
21. World Health Organization. COVID-19 clinical management: living guidance. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>. Accessed on: May 15 2021. 2021.
22. World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available from: [https://www.who.int/classifications/icd/Guidelines\\_Cause\\_of\\_Death\\_COVID-19-20200420-EN.pdf?ua=1](https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1). Document Number: WHO/HQ/DDI/DNA/CAT. Accessed on May 31, 2021. 2021.
23. Jacoby P, Kelly H. Is it necessary to adjust for calendar time in a test negative design?: Responding to: Jackson ML, Nelson JC. The test negative design for estimating influenza vaccine effectiveness. *Vaccine* 2013;31(April (17)):2165-8. *Vaccine* 2014;32:2942.
24. Pearce N. Analysis of matched case-control studies. *BMJ* 2016;352:i969.
25. Rothman KJ, Greenland S, Lash TL. *Modern epidemiology*. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
26. Planning and Statistics Authority- State of Qatar. Labor force sample survey. Available from: [https://www.psa.gov.qa/en/statistics/Statistical%20Releases/Social/LaborForce/2017/statistical\\_analysis\\_labor\\_force\\_2017\\_En.pdf](https://www.psa.gov.qa/en/statistics/Statistical%20Releases/Social/LaborForce/2017/statistical_analysis_labor_force_2017_En.pdf). Accessed on: May 01, 2020. 2017.
27. Qatar viral genome sequencing data. Data on randomly collected samples. <https://www.gisaid.org/phylogenetics/global/nextstrain/>. 2021. at <https://www.gisaid.org/phylogenetics/global/nextstrain/>.
28. Benslimane FM, Al Khatib HA, Al-Jamal O, et al. One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar. *Front Cell Infect Microbiol* 2021;11:768883.
29. World Health Organization. Tracking SARS-CoV-2 variants. Available from: <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>. Accessed on: June 5, 2021. 2021.
30. Makhoul M., Ayoub H.H., Chemaitelly H., et al. Epidemiological impact of SARS-CoV-2 vaccination: Mathematical modeling analyses. *Vaccines* 2020;8.
31. Usherwood T, LaJoie Z, Srivastava V. A model and predictions for COVID-19 considering population behavior and vaccination. *Scientific Reports* 2021;11:12051.
32. Andersson O, Campos-Mercade P, Meier AN, Wengström E. Anticipation of COVID-19 Vaccines Reduces Social Distancing. [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3765329](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3765329). SSRN 2021.

**Figure 1. Flowchart describing the population selection process for investigating mRNA-1273 vaccine effectiveness.**



\*Sample includes 3 persons who had another vaccination with mRNA-1273 and 491 persons who had another vaccination with BNT162b2

†Sample includes 47 persons who had another vaccination with mRNA-1273

‡Sample includes 15 persons who had another vaccination with mRNA-1273 and 2,821 persons who had another vaccination with BNT162b2

§Sample includes 331 persons who had another vaccination with mRNA-1273

**Note:** In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated (our reference group). Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

**Table 1. Demographic characteristics of subjects and reasons for PCR testing among samples used to estimate mRNA-1273 vaccine effectiveness. The table includes samples used in the 0-13-days-after-first-dose analysis, ≥14-days-after-first-dose-and-no-second-dose analysis, and 1st-month-after-second-dose analysis.**

Characteristics	0-13-days-after-first-dose			≥14-days-after-first-dose analyses			1 <sup>st</sup> -month-after-second-dose		
	Cases* (PCR-positive)	Controls* (PCR-negative)	SMD <sup>§</sup>	Cases* (PCR-positive)	Controls* (PCR-negative)	SMD <sup>§</sup>	Cases* (PCR-positive)	Controls* (PCR-negative)	SMD <sup>§</sup>
	N=89,767	N=151,005		N=88,192	N=149,086		N=87,509	N=148,349	
<b>Median age (IQR) — years</b>	30 (16-38)	30 (12-38)	0.05 <sup>†</sup>	30 (15-38)	30 (12-37)	0.04 <sup>†</sup>	30 (14-38)	30 (11-37)	0.04 <sup>†</sup>
<b>Age group — no. (%)</b>									
<20 years	23,670 (26.4)	41,895 (27.7)		23,668 (26.8)	41,909 (28.1)		23,654 (27.0)	41,872 (28.2)	
20-29 years	18,567 (20.7)	31,719 (21.0)		18,230 (20.7)	31,284 (21.0)		18,146 (20.7)	31,186 (21.0)	
30-39 years	28,060 (31.3)	46,707 (30.9)		27,439 (31.1)	45,975 (30.8)		27,165 (31.0)	45,678 (30.8)	
40-49 years	14,264 (15.9)	22,752 (15.1)	0.04	13,771 (15.6)	22,144 (14.9)	0.04	13,570 (15.5)	21,936 (14.8)	0.04
50-59 years	4,221 (4.7)	6,508 (4.3)		4,117 (4.7)	6,379 (4.3)		4,022 (4.6)	6,282 (4.2)	
60-69 years	769 (0.9)	1,109 (0.7)		748 (0.9)	1,083 (0.7)		738 (0.8)	1,080 (0.7)	
70+ years	216 (0.2)	315 (0.2)		219 (0.3)	312 (0.2)		214 (0.2)	315 (0.2)	
<b>Sex</b>									
Male	61,688 (68.7)	104,433 (69.2)	0.01	60,377 (68.5)	102,808 (69.0)	0.01	59,947 (68.5)	102,396 (69.0)	0.01
Female	28,079 (31.3)	46,572 (30.8)		27,815 (31.5)	46,278 (31.0)		27,562 (31.5)	45,953 (31.0)	
<b>Nationality<sup>†</sup></b>									
Bangladeshi	6,578 (7.3)	10,774 (7.1)	0.04	6,392 (7.3)	10,569 (7.1)	0.04	6,360 (7.3)	10,528 (7.1)	0.04
Egyptian	5,677 (6.3)	9,271 (6.1)		5,592 (6.3)	9,197 (6.2)		5,550 (6.3)	9,162 (6.2)	
Filipino	8,532 (9.5)	13,684 (9.1)		8,277 (9.4)	13,298 (8.9)		8,147 (9.3)	13,123 (8.9)	
Indian	24,372 (27.2)	42,010 (27.8)		23,876 (27.1)	41,418 (27.8)		23,665 (27.0)	41,262 (27.8)	
Nepalese	7,735 (8.6)	13,248 (8.8)		7,567 (8.6)	13,024 (8.7)		7,531 (8.6)	12,958 (8.7)	
Pakistani	4,960 (5.5)	8,592 (5.7)		4,908 (5.6)	8,529 (5.7)		4,881 (5.6)	8,520 (5.7)	
Qatari	11,961 (13.3)	21,413 (14.2)		11,968 (13.6)	21,437 (14.4)		11,912 (13.6)	21,364 (14.4)	
Sri Lankan	3,059 (3.4)	4,926 (3.3)		2,992 (3.4)	4,814 (3.2)		2,968 (3.4)	4,799 (3.2)	
Sudanese	2,408 (2.7)	3,875 (2.6)		2,363 (2.7)	3,823 (2.6)		2,325 (2.7)	3,777 (2.6)	
Other nationalities <sup>‡</sup>	14,485 (16.1)	23,212 (15.4)		14,257 (16.2)	22,977 (15.4)		14,170 (16.2)	22,856 (15.4)	
<b>Reason for PCR testing</b>									
Clinical suspicion	31,238 (34.8)	43,476 (28.8)	0.14	30,736 (34.9)	43,165 (29.0)	0.13	30,381 (34.7)	42,973 (29.0)	0.13
Contact tracing	15,077 (16.8)	26,243 (17.4)		14,834 (16.8)	26,008 (17.4)		14,663 (16.8)	25,650 (17.3)	
Healthcare routine testing	10,999 (12.3)	19,493 (12.9)		10,845 (12.3)	19,329 (13.0)		10,821 (12.4)	19,296 (13.0)	
Survey	21,676 (24.2)	41,258 (27.3)		21,195 (24.0)	40,400 (27.1)		21,026 (24.0)	40,136 (27.1)	
Individual request	10,469 (11.7)	20,115 (13.3)		10,278 (11.7)	19,774 (13.3)		10,304 (11.8)	19,874 (13.4)	
Other	308 (0.3)	420 (0.3)		304 (0.3)	410 (0.3)		314 (0.4)	420 (0.3)	

Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction; SMD, standardized mean difference.

\*Cases and controls were matched one-to-two by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.

<sup>†</sup>Nationalities were chosen to represent the most populous groups in Qatar.

<sup>‡</sup>These comprise 102 other nationalities in Qatar in the 0-13-days-after-first-dose analysis, 102 other nationalities in the ≥14-days-after-first-dose-and-no-second-dose analysis, and 102 other nationalities in the 1st-month-after-second-dose analysis.

<sup>§</sup>SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates adequate matching.

<sup>¶</sup>SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation.

**Table 2. Demographic characteristics of subjects and reasons for PCR testing among samples used to estimate mRNA-1273 vaccine effectiveness. The table includes samples used in the 2<sup>nd</sup>-month-after-second-dose analysis, 3<sup>rd</sup>-month-after-second-dose analysis, and 4<sup>th</sup>-month-after-second-dose analysis.**

Characteristics	2 <sup>nd</sup> -month-after-second-dose			3 <sup>rd</sup> -month-after-second-dose			4 <sup>th</sup> -month-after-second-dose		
	Cases* (PCR-positive)	Controls* (PCR-negative)	SMD <sup>§</sup>	Cases* (PCR-positive)	Controls* (PCR-negative)	SMD <sup>§</sup>	Cases* (PCR-positive)	Controls* (PCR-negative)	SMD <sup>§</sup>
	N=86,957	N=147,065		N=86,903	N=146,880		N=86,976	N=146,959	
<b>Median age (IQR) — years</b>	30 (14-38)	30 (11-37)	0.04 <sup>†</sup>	30 (11-37)	30 (14-38)	0.04 <sup>†</sup>	30 (14-38)	30 (11-37)	0.04 <sup>†</sup>
<b>Age group — no. (%)</b>									
<20 years	23,653 (27.2)	41,874 (28.5)		23,639 (27.2)	41,855 (28.5)		23,642 (27.2)	41,869 (28.5)	
20-29 years	18,051 (20.8)	30,884 (21.0)		18,023 (20.7)	30,861 (21.0)		18,032 (20.7)	30,869 (21.0)	
30-39 years	26,976 (31.0)	45,264 (30.8)		26,979 (31.0)	45,178 (30.8)		27,013 (31.1)	45,213 (30.8)	
40-49 years	13,408 (15.4)	21,557 (14.7)	0.04	13,415 (15.4)	21,543 (14.7)	0.04	13,426 (15.4)	21,555 (14.7)	0.04
50-59 years	3,935 (4.5)	6,129 (4.2)		3,917 (4.5)	6,093 (4.2)		3,931 (4.5)	6,101 (4.2)	
60-69 years	724 (0.8)	1,050 (0.7)		721 (0.8)	1,047 (0.7)		724 (0.8)	1,049 (0.7)	
70+ years	210 (0.2)	307 (0.2)		209 (0.2)	303 (0.2)		208 (0.2)	303 (0.2)	
<b>Sex</b>									
Male	59,526 (68.5)	101,364 (68.9)	0.01	59,479 (68.4)	101,225 (68.9)	0.01	59,513 (68.4)	101,223 (68.9)	0.01
Female	27,431 (31.6)	45,701 (31.1)		27,424 (31.6)	45,655 (31.1)		27,463 (31.6)	45,736 (31.1)	
<b>Nationality<sup>†</sup></b>									
Bangladeshi	6,316 (7.3)	10,408 (7.1)	0.04	6,291 (7.2)	10,357 (7.1)	0.04	6,294 (7.2)	10,358 (7.1)	0.04
Egyptian	5,507 (6.3)	9,070 (6.2)		5,505 (6.3)	9,063 (6.2)		5,512 (6.3)	9,079 (6.2)	
Filipino	8,126 (9.3)	13,065 (8.9)		8,111 (9.3)	13,022 (8.9)		8,128 (9.4)	13,080 (8.9)	
Indian	23,462 (27.0)	40,739 (27.7)		23,458 (27.0)	40,674 (27.7)		23,455 (27.0)	40,645 (27.7)	
Nepalese	7,507 (8.6)	12,914 (8.8)		7,497 (8.6)	12,882 (8.8)		7,481 (8.6)	12,856 (8.8)	
Pakistani	4,857 (5.6)	8,440 (5.7)		4,859 (5.6)	8,469 (5.8)		4,859 (5.6)	8,444 (5.8)	
Qatari	11,839 (13.6)	21,224 (14.4)		11,823 (13.6)	21,191 (14.4)		11,861 (13.6)	21,254 (14.5)	
Sri Lankan	2,943 (3.4)	4,753 (3.2)		2,939 (3.4)	4,741 (3.2)		2,952 (3.4)	4,751 (3.2)	
Sudanese	2,313 (2.7)	3,752 (2.6)		2,317 (2.7)	3,753 (2.6)		2,318 (2.7)	3,762 (2.6)	
Other nationalities <sup>‡</sup>	14,087 (16.2)	22,700 (15.4)		14,103 (16.2)	22,728 (15.5)		14,116 (16.2)	22,730 (15.5)	
<b>Reason for PCR testing</b>									
Clinical suspicion	30,124 (34.6)	42,421 (28.9)	0.13	30,104 (34.6)	42,310 (28.8)	0.13	30,154 (34.7)	42,373 (28.8)	0.13
Contact tracing	14,621 (16.8)	25,535 (17.4)		14,613 (16.8)	25,507 (17.4)		14,611 (16.8)	25,496 (17.4)	
Healthcare routine testing	10,802 (12.4)	19,252 (13.1)		10,798 (12.4)	19,245 (13.1)		10,801 (12.4)	19,248 (13.1)	
Survey	20,927 (24.1)	39,894 (27.1)		20,921 (24.1)	39,867 (27.1)		20,932 (24.1)	39,892 (27.1)	
Individual request	10,176 (11.7)	19,554 (13.3)		10,164 (11.7)	19,544 (13.3)		10,175 (11.7)	19,546 (13.3)	
Other	307 (0.4)	409 (0.3)		303 (0.4)	407 (0.3)		303 (0.4)	404 (0.3)	

Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction.

\*Cases and controls were matched one-to-two by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.

<sup>†</sup>Nationalities were chosen to represent the most populous groups in Qatar.

<sup>‡</sup>These comprise 102 other nationalities in Qatar in the 2<sup>nd</sup>-month-after-second-dose analysis, 102 other nationalities in the 3<sup>rd</sup>-month-after-second-dose analysis, and 102 other nationalities in the 4<sup>th</sup>-month-after-second-dose analysis.

<sup>§</sup>SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates adequate matching.

<sup>†</sup>SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation.

**Table 3. Demographic characteristics of subjects and reasons for PCR testing among samples used to estimate mRNA-1273 vaccine effectiveness. The table includes samples used in the 5th-month-after-second-dose analysis, 6th-month-after-second-dose analysis, 7th-month-after-second-dose, and 8th-month-after-second-dose analysis.**

Characteristics	5 <sup>th</sup> -month-after-second-dose			6 <sup>th</sup> -month-after-second-dose			7 <sup>th</sup> -month-after-second-dose			8 <sup>th</sup> -month-after-second-dose		
	Cases* (PCR- positive)	Controls* (PCR- negative)	SMD <sup>§</sup>									
	N=86,962	N=146,870		N=86,814	N=146,576		N=86,843	N=146,628		N=86,754	N=146,435	
<b>Median age (IQR) — years</b>	30 (14-38)	30 (11-37)	0.04 <sup>¶</sup>	30 (14-38)	30 (11-37)	0.05 <sup>¶</sup>	30 (14-38)	30 (11-37)	0.04 <sup>¶</sup>	30 (14-38)	30 (11-37)	0.04 <sup>¶</sup>
<b>Age group — no. (%)</b>												
<20 years	23,647 (27.2)	41,862 (28.5)		23,638 (27.2)	41,840 (28.5)		23,645 (27.2)	41,864 (28.6)		23,644 (27.3)	41,853 (28.6)	
20-29 years	18,027 (20.7)	30,834 (21.0)		17,990 (20.7)	30,776 (21.0)		17,989 (20.7)	30,766 (21.0)		17,963 (20.7)	30,720 (21.0)	
30-39 years	26,990 (31.0)	45,138 (30.7)		26,924 (31.0)	45,030 (30.7)		26,965 (31.1)	45,085 (30.8)		26,917 (31.0)	44,983 (30.7)	
40-49 years	13,434 (15.5)	21,567 (14.7)	0.04	13,403 (15.4)	21,487 (14.7)	0.04	13,399 (15.4)	21,486 (14.7)	0.04	13,381 (15.4)	21,449 (14.7)	0.04
50-59 years	3,929 (4.5)	6,111 (4.2)		3,927 (4.5)	6,092 (4.2)		3,916 (4.5)	6,079 (4.2)		3,915 (4.5)	6,076 (4.2)	
60-69 years	727 (0.8)	1,055 (0.7)		724 (0.8)	1,049 (0.7)		720 (0.8)	1,044 (0.7)		724 (0.8)	1,049 (0.7)	
70+ years	208 (0.2)	303 (0.2)		208 (0.2)	302 (0.2)		209 (0.2)	304 (0.2)		210 (0.2)	305 (0.2)	
<b>Sex</b>												
Male	59,513 (68.4)	101,201 (68.9)	0.01	59,442 (68.5)	101,056 (68.9)	0.01	59,425 (68.4)	101,020 (68.9)	0.01	59,386 (68.5)	100,939 (68.9)	0.01
Female	27,449 (31.6)	45,669 (31.1)		27,372 (31.5)	45,520 (31.1)		27,418 (31.6)	45,608 (31.1)		27,368 (31.6)	45,496 (31.1)	
<b>Nationality<sup>†</sup></b>												
Bangladeshi	6,287 (7.2)	10,347 (7.1)		6,280 (7.2)	10333 (7.1)		6,281 (7.2)	10,335 (7.1)		6,278 (7.2)	10,328 (7.1)	
Egyptian	5,526 (6.4)	9,099 (6.2)		5,516 (6.4)	9080 (6.2)		5,527 (6.4)	9,099 (6.2)		5,511 (6.4)	9,062 (6.2)	
Filipino	8,098 (9.3)	12,986 (8.8)		8,082 (9.3)	12953 (8.8)		8,088 (9.3)	12,962 (8.8)		8,062 (9.3)	12,901 (8.8)	
Indian	23,468 (27.0)	40,673 (27.7)		23,441 (27.0)	40608 (27.7)		23,467 (27.0)	40,657 (27.7)		23,439 (27.0)	40,602 (27.7)	
Nepalese	7,487 (8.6)	12,864 (8.8)		7,478 (8.6)	12842 (8.8)		7,471 (8.6)	12,818 (8.7)		7,468 (8.6)	12,810 (8.8)	
Pakistani	4,860 (5.6)	8,436 (5.7)	0.04	4,851 (5.6)	8422 (5.8)	0.04	4,845 (5.6)	8,405 (5.7)	0.04	4,845 (5.6)	8,404 (5.7)	0.04
Qatari	11,854 (13.6)	21,239 (14.5)		11,838 (13.6)	21182 (14.5)		11,827 (13.6)	21,187 (14.5)		11,829 (13.6)	21,191 (14.5)	
Sri Lankan	2,944 (3.4)	4,737 (3.2)		2,936 (3.4)	4728 (3.2)		2,929 (3.4)	4,717 (3.2)		2,929 (3.4)	4,717 (3.2)	
Sudanese	2,318 (2.7)	3,762 (2.6)		2,316 (2.7)	3754 (2.6)		2,319 (2.7)	3,762 (2.6)		2,313 (2.7)	3,750 (2.6)	
Other nationalities <sup>‡</sup>	14,120 (16.2)	22,727 (15.5)		14,076 (16.2)	22674 (15.5)		14,089 (16.2)	22,686 (15.5)		14,080 (16.2)	22,670 (15.5)	
<b>Reason for PCR testing</b>												
Clinical suspicion	30,153 (34.7)	42,336 (28.8)		30,084 (34.7)	42178 (28.78)		30,082 (34.6)	42,175 (28.8)		30,041 (34.6)	42,077 (28.7)	
Contact tracing	14,619 (16.8)	25,501 (17.4)		14,604 (16.8)	25485 (17.39)		14,603 (16.8)	25,481 (17.4)		14,599 (16.8)	25473 (17.4)	
Healthcare routine testing	10,801 (12.4)	19,251 (13.1)	0.13	10,800 (12.4)	19241 (13.13)	0.13	10,790 (12.4)	19,224 (13.1)	0.13	10,792 (12.4)	19226 (13.1)	0.13
Survey	20,927 (24.1)	39,865 (27.1)		20,884 (24.1)	39790 (27.15)		20,919 (24.1)	39,853 (27.2)		20,885 (24.1)	39780 (27.2)	
Individual request	10,156 (11.7)	19,509 (13.3)		10,143 (11.7)	19482 (13.29)		10,149 (11.7)	19,493 (13.3)		10,143 (11.7)	19484 (13.3)	
Other	306 (0.4)	408 (0.3)		299 (0.3)	400 (0.27)		300 (0.4)	402 (0.3)		294 (0.3)	395 (0.3)	

Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction.

\*Cases and controls were matched one-to-two by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test.

<sup>†</sup>Nationalities were chosen to represent the most populous groups in Qatar.

<sup>‡</sup>These comprise 102 other nationalities in Qatar in the 5th-month-after-second-dose analysis, 102 other nationalities in the 6th-month-after-second-dose analysis, 102 other nationalities in the 7th-month-after-second-dose analysis, and 102 other nationalities in the 8th-month-after-second-dose analysis.

<sup>§</sup>SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates adequate matching.

\*SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation.

**Table 4. Effectiveness of the mRNA-1273 vaccine against any SARS-CoV-2 infection and against any severe, critical, or fatal COVID-19.**

Sub-studies*	Effectiveness against infection					Effectiveness against hospitalization and death				
	Cases <sup>†</sup> (PCR-positive)		Controls <sup>†</sup> (PCR-negative)		Effectiveness in % (95% CI) <sup>‡</sup>	Cases <sup>†</sup> (Severe, critical, or fatal disease) <sup>§</sup>		Controls <sup>†</sup> (PCR-negative)		Effectiveness in % (95% CI) <sup>‡</sup>
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated		Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	
0-13 days after first dose	2,931	86,836	4,360	146,645	-2.2 (-7.6 to 2.9)	172	3,073	727	11,575	25.6 (10.6 to 38.1)
≥14 days after first dose and no second dose	962	87,230	3,891	145,195	65.5 (62.7 to 68.0)	28	3,066	464	11,379	83.1 (74.7 to 88.7)
1 <sup>st</sup> month after the second dose	416	87,093	4,701	143,648	88.5 (87.2 to 89.7)	4	3,068	414	11,359	97.4 (93.0 to 99.0)
2 <sup>nd</sup> month after the second dose	148	86,809	2,136	144,929	90.6 (88.7 to 92.1)	1	3,046	132	11,492	97.8 (83.7 to 99.7)
3 <sup>rd</sup> month after the second dose	146	86,757	1,493	145,387	86.5 (83.8 to 88.8)	0	3,049	68	11,553	100.0 (55.0 to 100.0) <sup>¶</sup>
4 <sup>th</sup> month after the second dose	186	86,790	1,221	145,738	80.7 (77.0 to 83.8)	2	3,043	52	11,556	91.5 (60.8 to 98.1)
5 <sup>th</sup> month after the second dose	192	86,770	902	145,968	72.1 (66.7 to 76.7)	1	3,046	44	11,566	93.8 (53.6 to 99.2)
6 <sup>th</sup> month after the second dose	105	86,709	494	146,082	70.6 (62.7 to 76.8)	1	3,042	10	11,583	67.6 (-165.6 to 96.0)
7 <sup>th</sup> month after the second dose	168	86,675	376	146,252	29.9 (13.1 to 43.5)	0	3,041	13	11,571	100.0 (-146.7 to 100.0) <sup>¶</sup>
8 <sup>th</sup> month or greater after the second dose	83	86,671	137	146,298	3.5 (-33.2 to 30.2)	0	3,043	11	11,581	100.0 (-194.4 to 100.0) <sup>¶</sup>

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

<sup>†</sup>In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

<sup>‡</sup>Cases and controls were matched one-to-two by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test in analysis of effectiveness against infection, and one-to-five in analysis of effectiveness against hospitalization and death.

<sup>§</sup>Vaccine effectiveness was estimated using the test-negative, case-control study design.<sup>9,10</sup>

<sup>¶</sup>Severity,<sup>21</sup> criticality,<sup>21</sup> and fatality<sup>22</sup> were defined as per World Health Organization guidelines.

<sup>¶</sup>Confidence interval could not be estimated using conditional logistic regression because of zero events among those vaccinated. Alternatively, the confidence interval was estimated using the standard error of the crude odds ratio after adding 0.5 to each of the number of vaccinated cases and number of unvaccinated cases.

**Table 5. Effectiveness of the mRNA-1273 vaccine against any SARS-CoV-2 infection and against any severe, critical, or fatal COVID-19, after adjusting for prior infection and healthcare worker status.**

Sub-studies*	Effectiveness against infection					Effectiveness against hospitalization and death				
	Cases <sup>†</sup> (PCR-positive)		Controls <sup>†</sup> (PCR-negative)		Effectiveness in % (95% CI) <sup>‡</sup>	Cases <sup>†</sup> (Severe, critical, or fatal disease) <sup>§</sup>		Controls <sup>†</sup> (PCR-negative)		Effectiveness in % (95% CI) <sup>‡</sup>
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated		Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	
0-13 days after first dose	2,931	86,836	4,360	146,645	-12.2 (-18.3 to -6.4)	172	3,073	727	11,575	22.1 (6.1 to 35.3)
≥14 days after first dose and no second dose	962	87,230	3,891	145,195	60.3 (57.0 to 63.3)	28	3,066	464	11,379	82.1 (73.1 to 88.1)
1 <sup>st</sup> month after the second dose	416	87,093	4,701	143,648	85.3 (83.5 to 86.9)	4	3,068	414	11,359	97.2 (92.4 to 99.0)
2 <sup>nd</sup> month after the second dose	148	86,809	2,136	144,929	84.7 (81.5 to 87.3)	1	3,046	132	11,492	97.4 (81.4 to 99.6)
3 <sup>rd</sup> month after the second dose	146	86,757	1,493	145,387	75.7 (70.5 to 80.1)	0	3,049	68	11,553	100.0 (55.0 to 100.0) <sup>¶</sup>
4 <sup>th</sup> month after the second dose	186	86,790	1,221	145,738	69.1 (62.5 to 74.5)	2	3,043	52	11,556	89.8 (51.9 to 97.8)
5 <sup>th</sup> month after the second dose	192	86,770	902	145,968	53.6 (42.9 to 62.3)	1	3,046	44	11,566	94.2 (55.0 to 99.2)
6 <sup>th</sup> month after the second dose	105	86,709	494	146,082	50.6 (34.5 to 62.8)	1	3,042	10	11,583	61.0 (-225.5 to 95.3)
7 <sup>th</sup> month after the second dose	168	86,675	376	146,252	-3.5 (-32.3 to 19.1)	0	3,041	13	11,571	100.0 (-146.7 to 100.0) <sup>¶</sup>
8 <sup>th</sup> month or greater after the second dose	83	86,671	137	146,298	-29.5 (-84.0 to 8.8)	0	3,043	11	11,581	100.0 (-194.4 to 100.0) <sup>¶</sup>

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

<sup>†</sup>In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

<sup>‡</sup>Cases and controls were matched one-to-two by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test in analysis of effectiveness against infection, and one-to-five in analysis of effectiveness against hospitalization and death.

<sup>§</sup>Vaccine effectiveness was estimated using the test-negative, case-control study design.<sup>9,10</sup>

<sup>¶</sup>Severity,<sup>21</sup> criticality,<sup>21</sup> and fatality<sup>22</sup> were defined as per World Health Organization guidelines.

<sup>¶¶</sup>Confidence interval could not be estimated using conditional logistic regression because of zero events among those vaccinated. Alternatively, the confidence interval was estimated using the standard error of the crude odds ratio after adding 0.5 to each of the number of vaccinated cases and number of unvaccinated cases.

**Table 6. Effectiveness of the mRNA-1273 vaccine against any SARS-CoV-2 infection and against any severe, critical, or fatal COVID-19, stratified by age (<50 years or ≥50 years).**

Sub-studies*	Effectiveness against infection					Effectiveness against hospitalization and death				
	Cases† (PCR-positive)		Controls† (PCR-negative)		Effectiveness in % (95% CI)‡	Cases† (Severe, critical, or fatal disease)§		Controls† (PCR-negative)		Effectiveness in % (95% CI)‡
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated		Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	
<b>Age &lt;50 years</b>										
0-13 days after first dose	2,579	81,982	3,944	139,129	-0.2 (-5.7 to 5.1)	113	2,161	565	9,211	26.6 (8.4 to 41.2)
≥14 days after first dose and no second dose	807	82,301	3,500	137,812	67.1 (64.3 to 69.7)	12	2,162	350	9,066	89.4 (80.5 to 94.3)
1 <sup>st</sup> month after the second dose	374	82,161	4,301	136,371	88.4 (87.0 to 89.7)	0	2,162	302	9,050	100.0 (88.9 to 100.0)¶
2 <sup>nd</sup> month after the second dose	133	81,955	2,011	137,568	90.7 (88.8 to 92.3)	1	2,154	106	9,174	97.1 (79.1 to 99.6)
3 <sup>rd</sup> month after the second dose	143	81,913	1,431	138,006	86.2 (83.4 to 88.6)	0	2,157	55	9,222	100.0 (37.1 to 100.0)¶
4 <sup>th</sup> month after the second dose	173	81,940	1,146	138,360	80.6 (76.7 to 83.8)	2	2,153	43	9,231	89.6 (50.1 to 97.8)
5 <sup>th</sup> month after the second dose	175	81,923	833	138,568	72.5 (66.8 to 77.2)	1	2,155	33	9,238	91.3 (33.9 to 98.8)
6 <sup>th</sup> month after the second dose	94	81,861	456	138,677	70.9 (62.6 to 77.3)	1	2,153	9	9,250	64.5 (-196.1 to 95.8)
7 <sup>th</sup> month after the second dose	155	81,843	353	138,848	31.1 (13.7 to 44.9)	0	2,152	12	9,237	100.0 (-202.8 to 100.0)¶
8 <sup>th</sup> month or greater after the second dose	74	81,831	116	138,889	-5.3 (-48.7 to 25.4)	0	2,152	6	9,251	100.0 (-541.5 to 100.0)¶
<b>Age ≥50 years</b>										
0-13 days after first dose	352	4,854	416	7,516	-23.1 (-44.8 to -4.6)	59	912	162	2,364	23.3 (-6.9 to 45.0)
≥14 days after first dose and no second dose	155	4,929	391	7,383	51.0 (39.5 to 60.4)	16	904	114	2,313	69.6 (46.8 to 82.6)
1 <sup>st</sup> month after the second dose	42	4,932	400	7,277	89.6 (84.8 to 92.9)	4	906	112	2,309	92.3 (78.6 to 97.2)
2 <sup>nd</sup> month after the second dose	15	4,854	125	7,361	88.7 (77.5 to 94.4)	0	892	26	2,318	100.0 (17.9 to 100.0)¶
3 <sup>rd</sup> month after the second dose	3	4,844	62	7,381	93.5 (78.9 to 98.0)	0	892	13	2,331	100.0 (-69.5 to 100.0)¶
4 <sup>th</sup> month after the second dose	13	4,850	75	7,378	82.1 (63.2 to 91.3)	0	890	9	2,325	100.0 (-150.5 to 100.0)¶
5 <sup>th</sup> month after the second dose	17	4,847	69	7,400	67.9 (41.2 to 82.4)	0	891	11	2,328	100.0 (-102.2 to 100.0)¶
6 <sup>th</sup> month after the second dose	11	4,848	38	7,405	67.7 (27.5 to 85.6)	0	889	1	2,333	100.0 (-3,812.7 to 100.0)¶
7 <sup>th</sup> month after the second dose	13	4,832	23	7,404	14.1 (-85.6 to 60.3)	0	889	1	2,334	100.0 (-3,814.3 to 100.0)¶
8 <sup>th</sup> month or greater after the second dose	9	4,840	21	7,409	47.2 (-34.6 to 79.3)	0	891	5	2,330	100.0 (-378.9 to 100.0)¶

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

<sup>8</sup>In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.

<sup>9</sup>Cases and controls were matched one-to-two by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test in analysis of effectiveness against infection, and one-to-five in analysis of effectiveness against hospitalization and death.

<sup>10</sup>Vaccine effectiveness was estimated using the test-negative, case-control study design.<sup>9,10</sup>

<sup>11</sup>Severity,<sup>21</sup> criticality,<sup>21</sup> and fatality<sup>22</sup> were defined as per World Health Organization guidelines.

<sup>12</sup>Confidence interval could not be estimated using conditional logistic regression because of zero events among those vaccinated. Alternatively, the confidence interval was estimated using the standard error of the crude odds ratio after adding 0.5 to each of the number of vaccinated cases and number of unvaccinated cases.

**Table 7. Effectiveness of the mRNA-1273 vaccine against symptomatic and asymptomatic SARS-CoV-2 infection.**

Sub-studies*	Effectiveness against symptomatic infection <sup>†</sup>					Effectiveness against asymptomatic infection <sup>‡</sup>				
	Cases <sup>§</sup> (PCR-positive)		Controls <sup>§</sup> (PCR-negative)		Effectiveness in % (95% CI) <sup>¶</sup>	Cases <sup>§</sup> (PCR-positive)		Controls <sup>§</sup> (PCR-negative)		Effectiveness in % (95% CI) <sup>¶</sup>
	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated		Vaccinated	Unvaccinated	Vaccinated	Vaccinated	
0-13 days after first dose	1,170	30,068	1,562	41,914	11.0 (3.4 to 18.0)	788	20,888	1,379	39,879	-9.9 (-21.3 to 0.5)
≥14 days after first dose and no second dose	303	30,433	1,572	41,593	78.3 (75.2 to 81.1)	299	20,896	1,078	39,322	54.6 (47.7 to 60.6)
1 <sup>st</sup> month after the second dose	79	30,302	1,720	41,253	94.4 (92.8 to 95.6)	139	20,887	1,022	39,114	79.9 (75.5 to 83.4)
2 <sup>nd</sup> month after the second dose	44	30,080	1,033	41,388	94.0 (91.8 to 95.6)	59	20,868	432	39,462	81.8 (75.2 to 86.6)
3 <sup>rd</sup> month after the second dose	52	30,052	814	41,496	91.2 (88.1 to 93.4)	56	20,865	241	39,626	66.1 (52.7 to 75.7)
4 <sup>th</sup> month after the second dose	87	30,067	676	41,697	82.9 (78.1 to 86.7)	64	20,868	231	39,661	63.6 (48.8 to 74.2)
5 <sup>th</sup> month after the second dose	94	30,059	552	41,784	76.7 (70.4 to 81.7)	63	20,864	148	39,717	33.7 (3.7 to 54.4)
6 <sup>th</sup> month after the second dose	55	30,029	301	41,877	74.8 (65.3 to 81.7)	30	20,854	73	39,717	30.8 (-13.0 to 57.6)
7 <sup>th</sup> month after the second dose	82	30,000	225	41,950	48.7 (30.3 to 62.2)	62	20,857	86	39,767	-46.6 (-115.6 to 0.2)
8 <sup>th</sup> month or greater after the second dose	35	30,006	64	42,013	20.0 (-29.0 to 50.3)	29	20,856	42	39,738	-28.4 (-129.3 to 28.1)

Abbreviations: CI, confidence interval; PCR, polymerase chain reaction.

<sup>†</sup>In each analysis for a specific time-since-vaccination stratum, we included only those vaccinated in this specific time-since-vaccination stratum and those unvaccinated. Only matched pairs of PCR-positive and PCR-negative persons, in which both members of the pair were either unvaccinated or fell within each time-since-vaccination stratum have been included in the corresponding vaccine effectiveness estimate. Thus, the number of cases (and controls) varied across time-since-vaccination analyses.


<sup>‡</sup>A symptomatic infection was defined as a PCR-positive test conducted because of clinical suspicion due to presence of symptoms compatible with a respiratory tract infection.

<sup>§</sup>An asymptomatic infection was defined as a PCR-positive test conducted with no reported presence of symptoms compatible with a respiratory tract infection, that is the PCR testing was done as part of a survey or a random testing campaign.

<sup>¶</sup>Cases and controls were matched one-to-two by sex, 10-year age group, nationality, reason for PCR testing, and calendar week of PCR test in analysis of effectiveness against infection, and one-to-five in analysis of effectiveness against hospitalization and death.

<sup>¶</sup>Vaccine effectiveness was estimated using the test-negative, case-control study design.<sup>9,10</sup>

**Figure 2. Effectiveness of the mRNA-1273 vaccine against A) any SARS-CoV-2 infection, B) severe, critical, or fatal COVID-19, C) symptomatic SARS-CoV-2 infection, and D) asymptomatic SARS-CoV-2 infection. Data are presented as effectiveness point estimates. Error bars indicate the corresponding 95% confidence intervals.**



The negative lower bound for the confidence interval was truncated for the estimate at 6th month after the second dose in Panel B, and for the estimate at 7th month after the second dose in Panels B and D, because the confidence intervals were too wide.

# Supplementary Appendix

## Table of contents

<b>Section S1. COVID-19 severity, criticality, and fatality classification .....</b>	<b>2</b>
<b>Section S2. Laboratory methods.....</b>	<b>3</b>
<b>Table S1. STROBE checklist for case-control studies. ....</b>	<b>4</b>
<b>References.....</b>	<b>6</b>

## **Section S1. COVID-19 severity, criticality, and fatality classification**

Severe Coronavirus Disease 2019 (COVID-19) disease was defined per the World Health Organization (WHO) classification as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected person with “oxygen saturation of  $<90\%$  on room air, and/or respiratory rate of  $>30$  breaths/minute in adults and children  $>5$  years old (or  $\geq 60$  breaths/minute in children  $<2$  months old or  $\geq 50$  breaths/minute in children 2-11 months old or  $\geq 40$  breaths/minute in children 1–5 years old), and/or signs of severe respiratory distress (accessory muscle use and inability to complete full sentences, and, in children, very severe chest wall indrawing, grunting, central cyanosis, or presence of any other general danger signs)”.<sup>1</sup> Detailed WHO criteria for classifying SARS-CoV-2 infection severity can be found in the WHO technical report.<sup>1</sup>

Critical COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with “acute respiratory distress syndrome, sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy”.<sup>1</sup> Detailed WHO criteria for classifying SARS-CoV-2 infection criticality can be found in the WHO technical report.<sup>1</sup>

COVID-19 death was defined per WHO classification as “a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID-19 disease (e.g. trauma). There should be no period of complete recovery from COVID-19 between illness and death. A death due to COVID-19 may not be attributed to another disease (e.g. cancer) and should be counted independently of preexisting conditions that are suspected of triggering a severe course of COVID-19”. Detailed WHO criteria for classifying COVID-19 death can be found in the WHO technical report.<sup>2</sup>

## **Section S2. Laboratory methods**

Nasopharyngeal and/or oropharyngeal swabs were collected for PCR testing and placed in Universal Transport Medium (UTM). Aliquots of UTM were: extracted on a QIA Symphony platform (QIAGEN, USA) and tested with real-time reverse-transcription PCR (RT-qPCR) using TaqPath COVID-19 Combo Kits (Thermo Fisher Scientific, USA) on an ABI 7500 FAST (Thermo Fisher, USA); tested directly on the Cepheid GeneXpert system using the Xpert Xpress SARS-CoV-2 (Cepheid, USA); or loaded directly into a Roche cobas 6800 system and assayed with a cobas SARS-CoV-2 Test (Roche, Switzerland). The first assay targets the viral S, N, and ORF1ab gene regions. The second targets the viral N and E-gene regions, and the third targets the ORF1ab and E-gene regions.

All PCR testing was conducted at the Hamad Medical Corporation Central Laboratory or Sidra Medicine Laboratory, following standardized protocols.

**Table S1. STROBE checklist for case-control studies.**

	Item No	Recommendation	Main text page
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Abstract
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Abstract
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	Introduction
<b>Methods</b>			
Study design	4	Present key elements of study design	Methods ('Study population, data sources, and study design')
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Methods ('Study population, data sources, and study design') & Figure 1
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	Methods ('Study population, data sources, and study design') & Figure 1
		(b) For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Methods ('Study population, data sources, and study design' & 'Statistical analysis'), Supp. Sections S1 & S2, & Figure 1
Data sources/measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Methods ('Study population, data sources, and study design' & 'Statistical analysis') & Tables 1-3
Bias	9	Describe any efforts to address potential sources of bias	Methods ('Study population, data sources, and study design' & 'Statistical analysis')
Study size	10	Explain how the study size was arrived at	Figure 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Methods ('Study population, data sources, and study design' & 'Statistical analysis') & Tables 1-3
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Methods ('Statistical analysis') & Tables 1-3
		(b) Describe any methods used to examine subgroups and interactions	Methods ('Statistical analysis')
		(c) Explain how missing data were addressed	NA, see Methods ('Study population, data sources, and study design')
		(d) If applicable, explain how matching of cases and controls was addressed	Methods ('Study population, data sources, and study design')
		(e) Describe any sensitivity analyses	Methods ('Statistical analysis')
<b>Results</b>			
Participants	13	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Figure 1
		(b) Give reasons for non-participation at each stage	
		(c) Consider use of a flow diagram	
Descriptive data	14	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Tables 1-3
		(b) Indicate number of participants with missing data for each variable of interest	NA, see Methods ('Study population, data sources, and study design')
Outcome data	15	Report numbers in each exposure category, or summary measures of exposure	Results, Figure 2, & Tables 4-5
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Results, Figure 2, & Tables 4-5
		(b) Report category boundaries when continuous variables were categorized	Tables 1-3
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Results & Tables 6-7

<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	Results
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Discussion pages 9-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Discussion page 10
Generalisability	21	Discuss the generalisability (external validity) of the study results	Discussion page 10
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Acknowledgements-page 11

Abbreviations: NA, not applicable; p. page; Supp. Supplementary Appendix.

## References

1. World Health Organization. COVID-19 clinical management: living guidance. Available from: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1>. Accessed on: May 15 2021. 2021.
2. World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available from: [https://www.who.int/classifications/icd/Guidelines\\_Cause\\_of\\_Death\\_COVID-19-20200420-EN.pdf?ua=1](https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1). Document Number: WHO/HQ/DDI/DNA/CAT. Accessed on May 31, 2021. 2021.